The abstract is read at the publisher; the summary is JClub's.
A DC-centric nanoengineering strategy couples antigen uptake with STING activation, suppressing tumor growth and metastasis in murine models while retaining activity in a humanized xenograft.
- Why it matters: STING agonists have limited antitumor efficacy because STING activation is not preferentially focused on dendritic cells that specialize in cross-priming.
- What they did: The approach uses dual ultra-pH-sensitive gating: mild tumor acidity unmasks the αCD47 cue to prime antigen acquisition, then a second acidic gate releases cGAMP for STING engagement in antigen-bearing DCs.
- The result: Antitumor efficacy requires Batf3-dependent cDC1s and CD8+ T cells, is preserved after macrophage depletion, and shows good tolerability in mice, with activity retained in a humanized cell-line-derived xenograft in NSG-SGM3 hosts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.